BioSpace News Archive

- The Federal, Provincial and Territorial Ministers of Health today issued the following statement: Canada , the response to the COVID-19 pandemic is built on a solid foundation of collaboration. We are witnessing this spirit in real time as front line workers, Indigenous partners, and federal, provincial and territorial governmemt

- DARZALEX FASPRO® Utilizing ENHANZE® Represents First and Only Approved Treatment for Patients with Newly Diagnosed AL Amyloidosis - - Accelerated Approval of DARZALEX FASPRO®-based Combination Regimen Supported by the PHASE 3 ANDROMEDA Study Demonstrating a Significantly Higher Hematologic Complete Response Rate in this Rare and Serious Blood Cell Disorder -

Accelerated approval of DARZALEX FASPRO®-based combination regimen supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder [15-January-2021] HORSHAM, Pa. , Jan. 15, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health Ireland (“Bausch Health”) relating to the License, Development and Commercialization Agreement (the “Agreement”) of Trulance®

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.